Updating the EMAS 2004/2005 clinical recommendations on postmenopausal therapy following the recent publications: WHI and Nurses' Health Study

Maturitas

Volumn 55, Issue 1, 2006, Pages 1-4

  Gompel, Anne ^a   Barlow, David ^a   Rozenberg, Serge ^a   Skouby, Sven O ^a  

^a FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

Clinical recommendations; Coronary heart disease; EMAS; EPT; ET; NHS; WHI

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE ACETATE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRACTICE GUIDELINE; PUBLICATION; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE;

EID: 33746257210     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2006.03.011     Document Type: Note

References (4)

1. Skouby S.O., Al-Azzawi F., Barlow D., et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 16;51 1 (2005) 8-14
2. http://emas.obgyn.net.
3. Hsia J., Langer R.D., Manson J.E., et al. Conjugated equine estrogens and coronary heart disease. The Women's Health Initiative. Arch Intern Med 166 (2006) 357-365
4. Grodstein F., Manson J.E., and Stampfer M.J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health 15 (2006) 35-44